PCV73 INCREASED PATIENT THROUGHPUT AND REDUCTION IN LABORATORY STAFF AND LABOR INTENSITY WITH THE USE OF REGADENOSON  by Smalarz, AM et al.
A154 Abstracts
Lombardy. The monthly cost in the ﬁ rst year was €1249 per person (77% attributable 
to HAs, 15% to pharmaceuticals and 8% to outpatient claims), decreasing to 
€309 in the following years (54% HAs, 31% pharmaceuticals, 16% outpatient).
CONCLUSIONS: This large study on the burden of AMI shows the epidemiologic,
economic and clinical impact of the disease. DENALI, with its large population 
followed over time is a powerful and dynamic tool for epidemiologic and health
economic research.
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OBJECTIVES: Acute coronary syndromes (ACS) are life-threatening disorders 
requiring intensive medical management or invasive cardiovascular procedures. CABG 
is an important therapeutic procedure among these patients. In Brazil almost 21,000 
CABG are performed in public hospitals costing the government R$7379.49 each in 
average. The aim of this study is to determine the direct medical costs of CABG among
different Brazilian regions in the private setting. METHODS: Retrospective single-
cohort study analyzed administrative claims data for patients with ACS submitted to 
CABG in 2007–2008. From a nationwide database with 1,801,344 people all the
patients with ACS submitted to CABG were selected. The patients were split according 
to the Brazilian geographical region where the procedure was performed. Student T 
test was used to compare the costs among three different regions. RESULTS: We 
identiﬁ ed 263 patients with ACS submitted to CABG. 67% of the procedures 
were performed in Southeast (SE) region, 25% in Middle West (MW) and 8% in the
south region. The average o SD, quartile 25%, median and 75% of the CABG cost 
of whole sample were R$15,849.72 o R$7,355.69, R$12,153.84, R$14,605.45 and
R$18,735.46, respectively. The same parameters for the SE, MW and S regions were,
respectively R$15,721.25oR$8,309.74, R$11,545.23, R$14,398.47 and R$18,657.87; 
R$16,744.15 o R$4,212.57, R$13,340.56, R$15,688.26 and R$19,325.96 and
R$14,035.03 o R$6,272.96, R$9,145.53, R$14,163.88 and R$17,103.31. There was 
no statistical difference among the different regions of Brazil of total CABG cost. There
was no statistical difference among the different regions and the total sample average.
CONCLUSIONS: The CABG average cost we found represent the average Brazilian
private setting health cost independent of the region studied. The average total CABG 
cost in the private setting is at least the double in relation to the average total CABG 
cost in the public setting.
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A CONCEPTUAL ANALYSIS OF THE COSTS OF CARE FOR A “MAJOR
BLEED” IN STUDIES OF ANTIPLATELET AND ANTITHROMBOTIC
THERAPIES
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OBJECTIVES: Antiplatelet and antithrombotic therapies have long been the focus of 
extensive clinical and economic investigations. In many of these studies, the primary 
endpoint of analysis was the incidence of “major bleeding.” Unfortunately, major 
bleeding does not have a standard or universal deﬁ nition. Major cardiovascular studies 
such as GUSTO, CURE, TIMI and the International Society on Thrombosis and 
Haemostasis (ISTH) have each established deﬁ nitions that result in vastly different
outcomes. Additionally, none of the common deﬁ nitions were designed for patients
undergoing surgery as part of their care. Analyses that compare outcomes from mul-
tiple trials must carefully examine the deﬁ nitions used. METHODS: We analyzed the
effect of applying 6 major bleeding deﬁ nitions on the incidence and costs of care for 
acute coronary syndrome (ACS) patients undergoing coronary artery bypass graft 
surgery (CABG) in their index hospitalization in a previously developed database of 
ACS patients from 14 health systems across the United States. RESULTS: Our com-
parison found that application of the different deﬁ nitions could result in a large 
variance in the primary outcome of “major bleeding” with equal impact on the com-
parisons for the cost of care. The incidence of major bleeding varied by as much as
50% as did the cost of treatment. The data review included ACS patients who under-
went CABG between January 2005 and December 2006. CONCLUSIONS: Compar-
ing the incidence, impact and costs of treating major bleeding between various clinical 
trials requires a careful assessment of the deﬁ nitions used. Development of a single 
standard deﬁ nition of “major bleeding” for use in clinical and observational trials is
recommended.
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COST-EFFECTIVENESS OF EZETIMIBE/SIMVASTATIN VERSUS
SIMVASTATIN: WILL THE INCREASED RISK OF CANCER MAKE
EZETIMIBE/SIMVASTATIN AN INAPPROPRIATE TREATMENT CHOICE?
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OBJECTIVES: Although ezetimbe/simvastatin (10/40 mg/day) combination therapy
may have a superior cholesterol-lowering proﬁ le and be more cost effective than statin 
monotherapy, recent data suggest an increased risk of cancer. We estimate the cost-
effectiveness of ezetimibe/simvastatin vs. simvastatin (40 mg/day) monotherapy, evalu-
ating the effect of this risk. METHODS: A Markov model, employing a 1-year cycle,
was employed to estimate the incremental cost, outcomes, and cost-effectiveness ratio
(ICER) over a 5-year time horizon. Efﬁ cacy data were obtained from the Simvastatin 
and Ezetimibe in Aortic Stenosis (SEAS) study, the Scandinavian Simvastatin Survival 
Study, and the Heart Protection Study. Costs were estimated from fee schedules,
diagnosis-related groups, and average wholesale prices. Utility weights were obtained 
from the peer-reviewed literature. All costs and outcomes after the ﬁ rst year were dis-
counted 3% annually in the base-case. Deterministic and probabilistic sensitivity 
analyses were conducted to evaluate the effect of parameter uncertainty and assump-
tions on the model results. A cost-effectiveness acceptability curve displays the prob-
ability that ezetimibe/simvastatin is cost effective. RESULTS: Ezetimibe/simvastatin 
was dominant (i.e., cost less, resulted in better outcomes) in the base-case scenario. 
For a 1 million-patient cohort, ezetimibe/simvastatin would cost $1,674,715,503 less 
than monotherapy and would result in 15,906 additional quality-adjusted life-years
(QALYs). One-way sensitivity analyses indicate that higher incidence of cancer, lower 
monotherapy costs, and higher risk of myocardial infarction (MI) reduce the cost-
effectiveness of ezetimibe/simvastatin substantially. According to probabilistic analy-
ses, ezetimibe/simvastatin is cost-effective at $50,000/QALY only 36.7% of the time; 
even at a willingness-to-pay of $100,000/QALY, ezetimibe/simvastatin is cost effective
less than 50% of the time. CONCLUSIONS: Although our study suggests that simv-
astatin/ezetemibe treatment is cost effective, policy makers should interpret these 
results in light of possible uncertainty surrounding the incidence of cancer, incidence
of myocardial infarction, and the true cost of simvastatin treatment following generic 
approval.
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OBJECTIVES: Persistent high blood pressure is one of the leading causes of microal-
buminuria and progression of nephropathy in patients with type 2 diabetes. A large
number of studies have shown effective reduction of microalbuminuria after antihy-
pertensive therapy and reducing progression of nephropathy to end-stage renal disease 
(ESRD). In the AVOID study aliskiren once daily as an add-on therapy provide a sig-
niﬁ cant additional reduction in proteinuria compared to losartan alone. The objective
of this model was to evaluate a long-term cost-utility of the two strategies. METHODS:
AVOID was a multinational, randomized, double-blind study to evaluate the possible
renoprotective effect of aliskiren in the primary endpoint – the change in the urinary
albumin to creatinine ratio (UACR) when added aliskiren to existing losartan and 
optimal antihypertensive therapy for six months in hypertensive patients with type 2 
diabetes and nephropathy. However the duration of this study was short to evaluate 
the incidence of ESRD. The AVOID cost-effectiveness Markov model is designed to 
estimate progression to ESRD using the primary endpoint of AVOID – superior reduc-
tion in UACR for aliskiren versus placebo – and project associated local costs and
clinical outcomes in Czech patients suffered by type 2 diabetes, hypertension and 
nephropathy. RESULTS: AVOID demonstrates that combination of aliskiren with
losartan showed systematically improved effectiveness compared with losartan 
alone. Effectiveness was expressed as QALY gained throughout the model time 
horizon. The incremental cost-effectiveness (ICER) of the aliskiren treatment in the
base case was below € 1027 per QALY gained and in the extended case improved
with real-life cost of dialysis and renal transplantation on cost-saving therapeutical
approach. CONCLUSIONS: Aliskiren once daily as add-on therapy to losartan is 
highly cost-effective option for hypertensive patients with type 2 diabetes and
nephropathy.
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OBJECTIVES: Regadenoson is a vasodilating stress agent used in patients undergoing
myocardial perfusion imaging (MPI) for detection of coronary artery disease. Its rapid
injection administration and weight-independent dosing may result in shortened
administration time versus adenosine or dipyridamole. We assessed whether the use 
of regadenoson results in overall MPI reduction in lab personnel time and consequen-
tially increased patient throughput. METHODS: An economic model was developed 
comparing regadenoson versus adenosine and dipyridamole on MPI laboratory pro-
ductivity and patient throughput through reduction in administration time and staff 
labor. We developed a pharmacologic stress agent survey (n  19) to evaluate the labo-
ratory personnel time and patient throughput. The results of this survey were used to 
populate the model. We included the administration of stress agents and managing 
associated adverse events for MPI. We solicited key opinion leaders including nurses, 
nuclear technologists and cardiologists to complete this survey in April and May of 
2008. RESULTS: Laboratory efﬁ ciency is reliant in part upon medication characteris-
tics (e.g. different stress agent dose, administration time, use of rapid injection vs. 
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infusion etc.). In measuring the number of tests conducted and time per test, i.e. labo-
ratory efﬁ ciency, we found that the use of regadenoson versus adenosine and dipyri-
damole could reduce the overall test time by 18 and 17 minutes respectively. Assuming
a baseline of 39 pharm-stress MPI tests per week for both adenosine and dipyridamole, 
the time saved per test using regadenoson translates into potentially servicing addi-
tional 330–366 patients per year. CONCLUSIONS: Due to its weight-independent
calculation and its administration via a rapid injection, the use of regadenoson may 
result in direct savings of laboratory personnel time and labor and the potential for 
increased patient throughput versus adenosine or dipyridamole. These time savings 
could lead to increased laboratory efﬁ ciencies (scheduling additional tests per week or 
reorganizing staff more efﬁ ciently).
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AMONG MANAGED CARE PRIMARY AND SECONDARY RISK MIXED
DYSLIPIDEMIA PATIENTS TREATED WITH FIXED DOSE NIACIN
EXTENDED-RELEASE AND SIMVASTATIN COMBINATION THERAPY
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OBJECTIVES: Compare predicted incremental reduction in hospital days and associ-
ated costs in managed health care (MHC) mixed dyslipidemia patient cohort treated 
with ﬁ xed-dose niacin extended-release and simvastatin (NERS) therapy. METHODS:
Two hypothetical formularies were modeled, a baseline formulary which did not 
include NERS and an adjusted formulary which did. Other lipid therapies included 
all marketed branded medications. The model was developed using product labeling,
clinical trial results, national prescription claims data, and a risk equation derived
from the HealthCore Integrated Research Database to estimate the incidence of car-
diovascular disease (CVD) events and associated hospital days avoided among patients 
achieving and not achieving optimal lipid values for LDL-C, HDL-C, and triglycerides 
(TG). Study patients included those aged q18 years with sub-optimal baseline LDL-C 
q 100 mg/dL, HDL-C a 40 mg/dL for males; a 50 mg/dL for females, and/or TG
levels q 150 mg/dL for females/diabetics; q 200 mg/dL for males/non-diabetics. A 
cost-effectiveness analysis was performed over three years evaluating the incremental
cost per hospital-day avoided after addition of NERS to current formulary. RESULTS:
Among 1,000,000 patients, 529,620 primary and secondary risk patients (52.96%) 
aged q 18 years were identiﬁ ed. Mean age at baseline was 54 o 11 years and 45%
was female. Over 3 years, there was reduction of 157 hospital days after addition
of NERS versus current formulary (54,839 vs. 54,997 days) along with a reduction
of $4,888,916 in total costs (sum of health plan costs, copayment, drug-monitoring 
costs, and CVD-event related costs) [$1,337,787,345 vs. $1,342,676,261], thus
achieving an incremental cost-saving of $31,041 per hospital day avoided. CONCLU-
SIONS: The MHC database-based model predicts that treating sub-optimal HDL-C 
and TG beyond achievement of optimal LDL-C goals may result in health care 
resource savings to a MHC organization after the addition of NERS to a managed
care formulary.
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes Studies
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IMPACT OF MEDICATION ADHERENCE ON CARDIOVASCULAR
DISEASE-RELATED HEALTH CARE COST AMONG PATIENTS TREATED
WITH FIXED DOSE COMBINATION VERSUS MULTI-PILL COMBINATION 
THERAPIES AMONG DYSLIPIDEMIA PATIENTS IN A MANAGED CARE
POPULATION
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OBJECTIVES: Assess the impact of optimal medication adherence on total cardiovas-
cular disease (CVD)-related total health care cost (THC) among dyslipidemia patients 
initiating ﬁ xed dose combination (FDC) therapy versus multi-pill combination (MPC) 
therapies in a managed care setting. METHODS: Study patients q 18 years were
identiﬁ ed as newly-initiating on FDC [Advicor: niacin extended release (NER) 
lovastatin] or MPC’s [simvastatin  NER (NER/S), lovastatin  NER (NER/L)] 
between January 1, 2000-June 30, 2006 [index date], with a minimum 6 months pre- 
and 12 months post-index health plan eligibility from a managed care database.
Multivariate generalized linear model was used to estimate association between opti-
mally adherent patients [Medication possession ratio (MPR) q 80%] and one-year
post-index CVD-related THC [sum of emergency room, inpatient, outpatient, and
medication costs] and sub-optimally adherent patients (MPR  80%) after controlling
for key demographic (age, gender) and clinical variables (FDC and MPC cohorts, 
comorbidity burden and number of non-dylipidemia medications). RESULTS: A total 
of 8988 patients (6638 FDC; 1687 NER/S; 663 NER/L) were identiﬁ ed. Those initiat-
ing FDC therapy were signiﬁ cantly younger [mean (SD) ages of 51.9 (10.5) vs. 56.0 
(9.8) years, p  0.0001] and had signiﬁ cantly lower baseline Deyo-Charlson comorbid-
ity scores (0.43 o 0.88 vs. 0.59 o 1.06; p  0.0001) versus MPC patients. At one year 
post-index, average MPR was higher among FDC patients versus both NER/S and
NER/L patients (0.54 o 0.35 vs. 0.50 o 0.35 and 0.47 o 0.34, respectively; p  0.01). 
After controlling for differences in baseline variables, multivariate regression showed
that patients with optimal adherence (MPR q 80%) had a 40% decrease in annual 
CVD-related THC versus sub-optimally adherent patients [Estimate: 0.601, 95% CI: 
0.427 – 0.845); p  0.003]. CONCLUSIONS: Optimal medication adherence among 
dyslipidemia managed care patients showed reduced CVD-related THC versus patients 
showing sub-optimal adherence. Further studies on early initiation of FDC therapy
targeting residual risk in dyslipidemia patients are warranted.
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RELATIONSHIP BETWEEN HEALTH LITERACY, OUTCOME
EXPECTATIONS, EFFICACY EXPECTATIONS AND MEDICATION
ADHERENCE
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OBJECTIVES: The purpose of this study was to test the theoretical model of whether 
patient’s efﬁ cacy expectations and outcome expectations mediate the relationship 
between health literacy and medication adherence. In addition, the relationships 
between patients’ demographic variables and their health literacy skills, outcome 
expectations, efﬁ cacy expectations and medication adherence were evaluated
METHODS: A survey composed of four validated instruments along with questions
related to patient’s demographic information was utilized. The four validated instru-
ments assessed functional health literacy (S-TOFHLA), medication related outcome 
expectations and efﬁ cacy expectations and medication adherence (MARS). The 
questionnaire was pretested by conducting a pilot study of 21 patients with hyperten-
sion at a community health clinic. RESULTS: In the main study 200 patients with 
hypertension completed the self-administered survey. Path analysis was used to test
the theoretical model. Age had statistically signiﬁ cant associations with health literacy 
scores (ñ  0.17, p  0.015), efﬁ cacy expectations (ñ  0.23, p  0.004), and medica-
tion adherence (ñ  0.27, p  0.0001). In addition, number of prescriptions taken 
daily and insurance (t  5.30, p  0.001) had a statistically signiﬁ cant association
with medication adherence (ñ  0.16, p  0.024). Health literacy was only variable
that was statistically correlated with income (ñ  0.21, p  0.003) and level of educa-
tion (ñ  0.29, p  0.001). Path analysis indicated that medication adherence was sig-
niﬁ cantly associated with age and efﬁ cacy expectations, which also was related to 
health literacy level, age and income. Health literacy was also a signiﬁ cant predictor 
of outcome expectations. Gender, level of education, and income were the only demo-
graphic variables signiﬁ cantly associated with health literacy scores. CONCLUSIONS:
The results of the study suggested that health literacy had an impact on medication
adherence through efﬁ cacy expectations.
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EVALUATION OF AN EDUCATIONAL ANTIHYPERTENSIVE MEDICATION
ADHERENCE TOOL: IMPACT ON ANTIHYPERTENSIVE ADHERENCE AND
BLOOD PRESSURE CONTROL
Bui CN1, Hanson KA2, Prasla K1, Godley PJ1, Frech-Tamas F2, Rascati KL3
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OBJECTIVES: Poor adherence to antihypertensive therapy increases patient risks 
of cardiovascular events. The objective of this study was to measure the effectiveness
of an individualized educational program on medication adherence and blood
pressure (BP) control. METHODS: This was a six-month, longitudinal study with a 
prospectively identiﬁ ed intervention group and a retrospective control group. The
Scott & White Health Plan enrollment and claim databases and EMR were utilized 
to identify continuously enrolled patients aged 18 years or older, diagnosed with 
hypertension, and treated with valsartan, aliskiren, or a ﬁ xed-dose combination of 
valsartan/hydrochlorothiazide or amlodipine/valsartan for at least three months 
prior to study enrollment. Patients meeting the inclusion criteria were invited to 
participate in the prospective intervention arm of the study, while those with geo-
graphic limitation served as controls. The intervention group received monthly per-
sonalized information about hypertension and treatment. A power analysis determined 
150 participants would be required in each arm to detect a 3% change in MPR. The 
intervention and control groups were matched based on demographic characteristics 
and Charlson Comorbidity Index score. All interval data were analyzed using paired 
t-tests, while categorical data were analyzed using chi-square tests. RESULTS: A
total of 159 patients enrolled into the study (60% female; mean [SD] age, 62 [12.6] 
years). Analysis of 95 matched patients showed no signiﬁ cant mean (SD) change in 
MPR (86% [0.2] to 83% [0.25] vs. 85% [0.24] to 82% [0.29]; P  0.8), systolic BP
(137.2 [15.1] to 136.3 [15] vs. 132.2 [14.8] to 136 [16.4] mmHg; P  0.2) and diastolic 
BP (72.6 [9.8] to 73.7 [13.1] vs. 72 [10.2] to 70.8 [10.5] mmHg; P  0.5) for the
intervention and control groups, respectively. CONCLUSIONS: Our pre liminary 
analysis showed no signiﬁ cant change in medication adherence and blood pressure. A 
complete analysis is necessary to determine the impact of the educational tool.
PCV78
INTERVENTIONS TO IMPROVE MEDICATION COMPLIANCE IN 
HYPERTENSION: QUALITATIVE AND QUANTITATIVE SYSTEMATIC
REVIEW
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OBJECTIVES: The objective of this systematic review was to evaluate the impact of 
interventions to improve medication compliance in patients on antihypertensive medi-
cations. METHODS: CINAHL, EMBASE, all EBM Reviews and MEDLINE electronic
databases were searched for articles published January 1979 through February 2007
using MeSH keywords relevant to patient compliance and intervention type, yielding
